GHK-Cu vs AHK-Cu: A Research-Use Comparison of Two Copper-Binding Tripeptides

Two copper-binding tripeptides, separated by a single atom. Swap the glycine at the N-terminus of GHK-Cu for an alanine and you have AHK-Cu — same histidine-anchored copper pocket, same blue cast, but a markedly different weight of evidence behind it. The chemistry is nearly siblings; the literature is not.

GHK-Cu and AHK-Cu are sold strictly for research use only (RUO), and both serve laboratories as model systems for copper coordination chemistry and copper-dependent cell signalling. What follows is a sober reading of what the verifiable literature actually demonstrates — and, just as importantly, where it stops. No dosing, no administration guidance, no therapeutic claims of any kind.

What are GHK-Cu and AHK-Cu, chemically?

Both belong to the histidine-containing copper-peptide family, in which an N-terminal amine, the imidazole of histidine, and the peptide backbone assemble a coordination pocket that chelates a Cu(II) ion — the canonical Xxx-His copper-binding motif. The bound copper is what lends each compound its characteristic blue or blue-green colour.

GHK-Cu is glycyl-L-histidyl-L-lysine complexed with copper(II). Its provenance is unusually well documented: it was first identified in 1977, when a growth-modulating activity in human serum was traced to this single tripeptide¹. Its structure has since been characterised in detail, including its use as a crystallisation tag that exploits its tight Cu(II) chelation⁸. AHK-Cu is alanyl-histidyl-lysine complexed with copper(II) — the same scaffold with alanine standing in for the N-terminal glycine. That lone substitution alters the local geometry and lipophilicity near the metal centre while preserving the His-anchored binding motif. A small change on paper; an open question in the lab.

How do the two products compare?

Side-by-side specifications for the two copper tripeptides as supplied by Condor Research. Note the added chlorine in the AHK-Cu formula and the heavier molecular weight, reflecting the alanine substitution and the supplied salt form.

What does the research explore for GHK-Cu?

GHK-Cu is among the most studied small peptides in regenerative and copper-homeostasis research, and the depth shows. In cell-culture and animal models it has been examined as a copper-delivery peptide that engages a broad set of pathways, including remodelling-related gene expression and tissue-repair signalling²³. Reviews have associated the GHK-Cu complex with modulation of large numbers of human genes in transcriptomic datasets³ — though such findings derive from laboratory systems, not controlled human trials, and that distinction matters more than the headline numbers. On the chemistry, the thermodynamics of its Cu(II) binding have been quantified directly by isothermal titration calorimetry alongside the related DAHK peptide⁴, giving GHK-Cu a well-defined and reproducible chemical profile.

1977 the year a growth-modulating activity in human serum was traced to the GHK tripeptide — nearly five decades of accumulated preclinical work that AHK-Cu has no equivalent of.

What does the research explore for AHK-Cu?

AHK-Cu’s literature is narrower and more biochemical. A 2007 in vitro and ex vivo study reported that the alanyl-histidyl-lysine copper complex influenced human dermal papilla cells and hair-follicle elongation⁵ — notably, one of the very few studies on the AHK-Cu compound itself. A separate construct conjugating AHK to vitamin C was investigated for BMP-2-induced osteogenic differentiation in mouse myoblasts⁶. Beyond those, the chemical backdrop rests largely on coordination studies of closely related His-containing tripeptides, which map how such scaffolds bind and redox-silence copper⁷⁴.

Much of what is “known” about AHK-Cu is inferred from its family rather than measured on the molecule directly.

That caveat is not pedantry. The Ala-His-His coordination work cited above⁷ characterises a related scaffold, not AHK-Cu proper — it is family context, not direct evidence. Treating analogy as data is the single most common way to overstate this compound.

Preclinical or clinical — where does the evidence actually sit?

This is the most important honest distinction. Both peptides sit predominantly in the preclinical domain. The mechanistic claims above come from in vitro assays, cell culture, biochemical and biophysical characterisation, and some animal models. For GHK-Cu, the volume and consistency of that preclinical work is substantial, and copper-peptides appear across the broader cosmetic-science and wound-research literature; even so, robust, peptide-specific randomised controlled trials remain limited, and review articles should not be mistaken for clinical proof. For AHK-Cu the evidence is thinner still — a handful of in vitro and ex vivo reports, with no substantial clinical dataset. Neither compound is established as safe or effective in humans, and neither is a drug, cosmetic, or supplement. Every finding summarised here describes biological activity observed under laboratory conditions only.

Which is “better” for a research programme?

There is no universal answer; the choice follows the experimental question, not a potency ranking. Investigators after the most heavily characterised copper-delivery peptide — the richest comparative literature, the best-mapped Cu(II)-binding profile — typically reach for GHK-Cu. Those probing how the N-terminal residue alters coordination geometry, lipophilicity, or hair-follicle-model behaviour, or who simply need a structural analogue for comparative chemistry, may select AHK-Cu. Many coordination-chemistry studies run both in parallel precisely because the contrast is the point.

Both Condor Research vials are supplied at ≥99% HPLC purity with a Certificate of Analysis and third-party batch testing, and both are intended exclusively for qualified research professionals. For laboratory research use only (RUO). Not for human or veterinary use, ingestion, or diagnostic application. No therapeutic or cosmetic claims are made or implied.